"FILMIX®" PUBLICATIONS (and related Microbubble-Research Publications)


A. TARGETED IMAGING OF TUMORS: [TOP OF PAGE]


1. Simon, R.H., S.Y. Ho, J.S. D'Arrigo, A. Wakefield, & S.G. Hamilton. (1990). Lipid-coated ultrastable microbubbles as a contrast agent in neurosonography. Investigative Radiology 25:1300-1304.
Abstract
Sample Illustrations (with captions): #1 (size - 46.7K), #2 (size - 67.7K), #3 (size - 35.4K)

2. D'Arrigo, J.S. (1991). Contrast-assisted tumor detection. Drug News & Perspectives 4:164-167.
Abstract

3. D'Arrigo, J.S., R.H. Simon, & S.Y. Ho. (1991). Lipid-coated uniform microbubbles for earlier sonographic detection of brain tumors. J. Neuroimaging 1:134-139.
Abstract
Sample Illustrations (with captions): #1 (size - 48.3K)

4. Simon, R.H., S.Y. Ho, C.R. Perkins, & J.S. D'Arrigo. (1992). A quantitative assessment of tumor enhancement by ultrastable lipid-coated microbubbles as a contrast agent. Investigative Radiology 27:29-34.
Abstract
Sample Illustrations (with captions): #1 (size - 63.6K)

5. D'Arrigo, J.S., & T. Imae. (1992). Physical characteristics of ultrastable lipid-coated microbubbles. J. Colloid & Interface Sci. 149:592-595.
Abstract
Sample Illustrations (with captions): #1 (size - 147.K)

6. D'Arrigo, J.S., S.Y. Ho, & R.H. Simon. (1993). Detection of experimental rat liver tumors by contrast-assisted ultrasonography. Investigative Radiology 28:218-222.
Abstract
Sample Illustrations (with captions): #1 (size - 13.5K), #2 (size - 176.K)

7. Huang, W., J.C. Grecula, T.M. Button, D.P. Harrington, M.A. Davis, J.S. D'Arrigo, B.H. Laster, & C.S. Springer. (1993). Use of lipid-coated microbubbles (LCMs) for susceptibility-based MRI contrast in brain tumors. Proceedings of the 12th Annual Meeting of the Society of Magnetic Resonance in Medicine, August 1993, New York, NY.


B. TARGETED CAVITATION-THERAPY OF TUMORS: [TOP OF PAGE]


8. Simon, R.H., S.Y. Ho, D.F. Uphoff, S.C. Lange, & J.S. D'Arrigo (1993). Applications of lipid-coated microbubble ultrasonic contrast to tumor therapy. Ultrasound in Medicine & Biology 19:123-125.
Abstract


C. TARGETED DRUG-DELIVERY TO TUMORS: [TOP OF PAGE]


9. Barbarese, E., S.Y. Ho, J.S. D'Arrigo, & R.H. Simon. (1995). Internalization of microbubbles by tumor cells in vivo and in vitro. J. Neuro-Oncology 26:25-34.
Abstract
Sample Illustrations (with captions): #1 (size - 93.9K), #2 (size - 165.K)

10. Ho, S.Y., E. Barbarese, J.S. D'Arrigo, C. Smith, & R.H. Simon. (1997). Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in tumor therapy. Neurosurgery 40:1260-1268.
Abstract
Sample Illustrations (with captions): #1 (size - 185.K), #2 (size - 151.K)


D. TARGETED DRUG-DELIVERY TO NEURO-INJURY SITES: [TOP OF PAGE]


11. Ho, S.Y., X.G. Li, A. Wakefield, E. Barbarese, J.S. D'Arrigo, & R.H. Simon. (1997). The affinity of lipid-coated microbubbles for maturing brain injury sites. Brain Res. Bull. 43:543-549.
Abstract

12. Wakefield, A.F., S.Y. Ho, X.G. Li, J.S. D'Arrigo, & R.H. Simon. (1998). The use of lipid-coated microbubbles as a delivery agent for 7B-hydroxycholesterol to a radiofrequency lesion in the rat brain. Neurosurgery 42:592-598.
Abstract

13. Kureshi, I.U., S.Y. Ho, H.C. Onyiuke, A.E. Wakefield, J.S. D'Arrigo, & R.H. Simon. (1999). The affinity of lipid-coated microbubbles to maturing spinal cord injury sites. Neurosurgery 44:1047-1053.
Abstract


E. BACKGROUND PUBLICATIONS (i.e., Natural-Microbubble studies, and Patents): [TOP OF PAGE]


Dilute gas-in-liquid emulsions, existing in natural waters, represent self-assembled (i.e., "self-organized") coated microbubbles (cf. D'Arrigo, 2010 [in press]) -- and is a topic of great concern to workers in many fields of fundamental and engineering sciences. Specifically, the existence of stable gas microcavities or microbubbles in fresh water, sea water, and other aqueous liquids including physiological fluids has been postulated and/or demonstrated by numerous investigators over the last half century. However, there is far less agreement in the scientific literature as to the predominant physicochemical/biochemical mechanism by which such gas microbubbles, 0.5 ~ 100 µm in diameter, are stabilized. A detailed knowledge of this physicochemical/biochemical stabilization mechanism in aqueous media is of practical importance to numerous and varied fields: hydrodynamic and acoustic cavitation, hydraulic and ocean engineering, waste-water treatment, commercial oil recovery, chemical oceanography, meteorology, marine biology, food technology, and a variety of medical applications including echocardiology, decompression sickness and, more recently, cancer diagnosis and treatment. Many of the above diverse applications (along with the underlying chemical and physical principles or considerations upon which they are based) are described individually in the publications following.

  1. D'Arrigo, J.S. (2003). Stable Gas-in-Liquid Emulsions: Production in Natural Waters and Artificial Media, Second edition, 323 pp.; Elsevier Science Publishers, Amsterdam and NY.
  2. D'Arrigo, J.S. (1986). Stable Gas-in-Liquid Emulsions: Production in Natural Waters and Artificial Media, 220 pp.; Elsevier Science Publishers, Amsterdam and NY.
  3. D'Arrigo, J.S. (1984). Surface properties of microbubble-surfactant monolayers at the air/water interface. J. Colloid & Interface Sci. 100:106-111.
  4. D'Arrigo, J.S., C. Saiz-Jimenez, & N.S. Reimer. (1984). Geochemical properties and biochemical composition of the surfactant mixture surrounding natural microbubbles. J. Colloid & Interface Sci. 100:96-105.
  5. D'Arrigo, J.S. (1983). Biological surfactants stabilizing natural microbubbles in aqueous media. Adv. Colloid & Interface Sci. 19:253-307.
  6. D'Arrigo, J.S. (1982). Glycoprotein surfactants stabilize long-lived gas microbubbles in the environment. In: Microbial-Enhanced Oil Recovery, ed. by J.E. Zajic, pp.124-140. PennWell Press, Tulsa.
  7. D'Arrigo, J.S. (1981). Aromatic proteinaceous surfactants stabilize long-lived gas microbubbles from natural sources. J. Chemical Physics 75:962-968.
  8. D'Arrigo, J.S. (1980). Structural features of the nonionic surfactants stabilizing long-lived bubble nuclei. J. Chemical Physics 72:5133-5138.
  9. D'Arrigo, J.S., & Y. Mano. (1979). Bubble production in agarose gels subjected to different decompression schedules. Undersea Biomed. Res. 6:93-98.
  10. D'Arrigo, J.S. (1979). Physical properties of the nonionic surfactants surrounding gas cavitation nuclei. J. Chemical Physics 71:1809-1813.
  11. Mano, Y., & J.S. D'Arrigo. (1978). The relationship between CO2 levels and decompression sickness: Implications for disease prevention. Aviation, Space & Environ. Med. 49:349-355.
  12. D'Arrigo, J.S. (1978). Improved method for studying the surface chemistry of bubble formation. Aviation, Space & Environ. Med. 49:358-361.
  13. Yount, D.E., T.D. Kunkle, J.S. D'Arrigo, F.W. Ingle, C. Yeung, & E.L. Beckman. (1977). Stabilization of gas cavitation nuclei by surface-active compounds. Aviation, Space & Environ. Med. 48:185-191.
  14. D'Arrigo, J.S. (1977). Dissolved carbon dioxide: Evidence for a significant role in the etiology of decompression sickness. In: Proceedings of the Fourth Joint Meeting of the Panel on Diving Physiology and Technology, U.S.-Japan Cooperative Program in Natural Resources (UJNR), ed. by J.W. Miller, pp. 88-100. Buffalo, New York.
  15. D'Arrigo, J.S. (1987). Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures. United States Patent No. 4,684,479.
  16. ibid. (2nd edition, revised 1990), Canada Patent No. 1,267,055.
  17. ibid. (3rd edition, revised 1994), Japan Patent No. 1,815,442.
  18. D'Arrigo, J.S. (1993). Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles. United States Patent No. 5,215,680.
  19. ibid. (2nd edition, revised 1995), Australia Patent No. 657480.
  20. ibid. (3rd edition, revised 1997), European P.O. Patent No. 0467031.
  21. ibid. (3rd edition), Germany Patent No. DE69127032T2.
  22. ibid. (3rd edition), United Kingdom Patent No. 0467031.
  23. ibid. (3rd edition), France Patent No. 0467031.
  24. ibid. (3rd edition), Italy Patent No. 0467031.


[ NOTE: Many other detailed research studies have been published describing (the structure and/or properties of) OTHER types of "lipid-encapsulated" microbubbles -- but which are NOT modeled primarily from the stabilized microbubbles in natural waters (i.e., do NOT have the same exact molecular composition nor identical properties as Filmix® ). For additional background information (via the free "PubMed" database at www.nlm.nih.gov) and for purposes of comparative review by any interested readers, a partial list of the numerous authors who have published on these OTHER types of "lipid-shell" microbubbles is provided as follows: Allen JS, Anderson T, Block SH, Borden MA, Brandenburger GH, Brayman AA, Bull JL, Bussat P, Carpenter JE, Chomas JE, Christiansen JP, Coggins MP, Crum LA, Dayton PA, de Haen C, de Jong N, Ellegala DB, Erxiong L, Ferrara KW, Fisher NG, French BA, Fritz TA, Gies RA, Gut J, Hilgenfeldt S, Hossack JA, Jayaweera AR, Kaul S, Klibanov AL, Kohno M, Kruse DE, Lancee CT, Lanza GM, Leong-Poi H, Ley K, Lindner JR, Longo M, Marmottant P, Matula T, McDicken WN, Miller DL, Moran CM, Morgan KE, Modzelewski RA, Patel DN, Postema M, Price RJ, Pu G, Pye SD, Runner GJ, Rychak JJ, Sakakima Y, Schneider M, Sboros V, Shaffrey ME, Shortencarier MJ, Skalek TC, Sklenar J, Skyba DM, Song JI, Tachibana K, Tachibana S, Takeuchi H, Taylor RP, ten Cate FJ, Unger EC, van Wamel A, Villanueva FS, Wagner WR, Weller GE, Wickline SA, Wilson SR, Wong MK, Wrigley RH, Yan F.]


F. LATEST STUDIES ( -- recent publications/presentations on "microbubble/particle [LCM/nanoparticle]" agent, i.e., Filmix® lipid nanoemulsion): [TOP OF PAGE]


xvii) D'Arrigo, J.S. (2020) Nanotargeting of drug(s) for delaying dementia: Relevance of Covid-19 impact on dementia. (Submitted for publication.)

xvi) Ariviyal Publishing (2020) News Release: "Biobased nanocarrier of drug(s) to both ameliorate COVID-19 illness symptomatology and, thereby, delay progression of Alzheimer's disease". (Accepted for publication.)

xv) D'Arrigo, J.S. (2020) Nanotargeting dementia etiology: Aiming drug nanocarriers toward receptors for vascular endothelium, serum amyloid A, inflammasomes, and oxidative stress. Nano Prog., 2(3), 25-30.

xiv) D'Arrigo, J.S. (2020) Biomimetic nanocarrier targeting drug(s) to upstream-receptor mechanisms in dementia: Focusing on linking pathogenic cascades. Biomimetics, 5(1), 11.

xiii) D'Arrigo, J.S. (2020) Biomaterial to improve drug delivery in Alzheimer's disease: Linking major pathogenic pathways. OBM Geriatrics, 4(1), 10.

xii) D'Arrigo, J.S. (2019) Delaying dementia: Targeted brain delivery using lipid cubic phases. OBM Neurobiology 3(3), doi:10.21926/obm.neurobiol.1903040 .

xi) D'Arrigo, J.S. (2019) Treating dementia early: Limiting cellular damage in brain tissue. OBM Geriatrics, 3(2), 19.

x) D'Arrigo, J.S. (2019) Nanotherapy to delay cognitive impairment: Using colloidal nanocarriers to block amyloid-beta-induced damage in brain cell membranes. SDRP J. Nanotech. Mat. Sci., 2(1), 94-105.

ix) D'Arrigo, J.S. (2018) Dementia Confidential: Aiming for Normal Aging, versus Dementia. 74 pp.; Lambert Academic Publishing, Germany.

viii) D'Arrigo, J.S. (2018) Targeting early dementia: Using lipid cubic phase nanocarriers to cross the blood-brain barrier. Biomimetics, 3(1), 4; doi: 10.3390/biomimetics3010004 .

vii) D'Arrigo, J.S. (2018) Treating early dementia: Drug targeting and circumventing the blood-brain barrier. Geriatr. Med. Care, 1(2), 1-7; doi: 10.15761/GMC.1000111 .

vi) D'Arrigo, J.S. (2018) Nanotherapy for Alzheimer's disease and vascular dementia: targeting senile endothelium. Adv. Colloid Interface Sci., 251, 44-54. [Chemistry Research Network ( ChemRN ) preprint server, posted 9-22-17, manuscript #3041744; BITSS Preprints server, posted 10-08-17, osf.io/preprints/bitss/9afh2, doi: 10.17605/osf.io/xyaj3, ARK: c7605/osf.io/xyaj3 .]

v) D'Arrigo, J.S. (2017) Alzheimer's disease, brain injury, and C.N.S. nanotherapy in humans: sonoporation augmenting drug targeting. Medical Sciences, 5(4), 29; doi: 10.3390/medsci5040029 (under Neurosciences section; -- invited article in the Special Issue "Advances in the Pathogenesis of Neurodegenerative Diseases"). [ MDPI Preprints server, posted 9-30-17, preprints.org/manuscript/201709.0166/v1; (doi: 10.20944/preprints201709.0166,v1).]

iv) D'Arrigo, J.S. (2015) Nanotherapy for Alzheimer's. Chemical & Engineering News, Vol. 93 (Oct. 19 issue): p. 2

iii) D'Arrigo, J.S. (2012) Stable Nanoemulsions: Self-Assembly in Nature and Nanomedicine (Chinese translation). 468 pp.; Ke'Ai Communications Publishing, Beijing.

ii) D'Arrigo, J.S. (2011) Stable Nanoemulsions: Self-Assembly in Nature and Nanomedicine. 436 pp.; Elsevier, Amsterdam and Oxford.

i) D'Arrigo, J.S. (2010) "Self-Assembling Nanoemulsions" [slide show; -- see below]

Stable nanoemulsions slide show (ppt) from cavcon



GO BACK TO MAIN PAGE